New antimetabolites in cancer chemotherapy and their clinical impact
about
Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancerReconstruction of Tissue-Specific Metabolic Networks Using CORDAScreening of DHFR-binding drugs by MALDI-TOFMS.Cancer incidence and adverse pregnancy outcome in registered nurses potentially exposed to antineoplastic drugs.A WKYMVm-containing combination elicits potent anti-tumor activity in heterotopic cancer animal model.First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysisPlasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibitionNucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy.Antimetabolite Treatment for Pancreatic Cancer.Targeting One Carbon Metabolism with an Antimetabolite Disrupts Pyrimidine Homeostasis and Induces Nucleotide Overflow.Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.Autophagy and cancer: taking the 'toxic' out of cytotoxics.Targeting glucose metabolism in patients with cancer.Design, synthesis and pharmacophoric model building of new 3-alkoxymethyl/3-phenyl indole-2-carboxamides with potential antiproliferative activity.Identifying anti-growth factors for human cancer cell lines through genome-scale metabolic modeling.Identification of factors involved in dimorphism and pathogenicity of Zymoseptoria tritici.Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines.The effect of 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline on cell growth, cell cycle, induction of DNA fragmentation, and activity of caspase 3 in murine leukemia L1210 cells and fibroblast NIH-3T3 cells.Therapeutic effects of gemcitabine on cutaneous manifestations in an Adamantiades-Behçet's disease-like mouse model.Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial.Immunotherapies: Exploiting the Immune System for Cancer Treatment.
P2860
Q28066481-B963E31F-621E-47C8-93BF-E669567C038DQ28388815-38781442-E09B-455E-8971-4D71BF658F08Q33374552-E84E6118-08F6-4E62-8505-9A05DCD1A143Q33693999-E55A331D-1277-45E6-8042-C02E6BCE02B3Q34147593-7BD91233-8BC2-40A3-A7D5-AE2B501BE11FQ34187204-5F72467A-DAFE-4642-8B4C-442DECCCB6FCQ34195332-8EC6AFE9-56FF-4F07-BCA6-A43DBA4FCACAQ34734085-08377477-82C1-4472-A29D-1448B1494A68Q35092019-6D56B451-22AB-4BB6-B3E2-9E453436B46BQ35567292-622252E9-472E-4175-B102-48B6F40C3A9BQ35826334-D9AD7037-76ED-4073-9C80-7B5E7E451F3BQ37008970-8D51FFE7-BF4E-47B3-AB44-1C5B414D3B21Q37180971-813537FC-2FF6-4E44-BD14-4C9453402A3AQ38104448-7176AE10-A0E6-4DA1-8AE7-AFA3327B1A7CQ38174427-D7B712EE-931A-468F-886B-97FB59D27AF8Q38778055-76134D4F-2958-46E4-A885-DCA2ADB0E3A0Q38914252-414D56FE-B01F-402F-B7E2-ADC21FB83157Q40084343-E9B16083-05C5-4317-997B-F7BC7F6E28E5Q40178610-5443FDA9-7C3A-4F79-9CE8-C489BD74D9EDQ40341242-39320DB2-B0F2-4A5E-8FFF-1215F458B472Q45077731-22029F18-8730-4EC2-A162-353AB4E3D9E8Q46116355-AADA0CAD-BAF6-47E4-99CA-BDE997EFA6A8Q55362851-68CF05ED-28FB-440A-8A3D-34C4B7223EDB
P2860
New antimetabolites in cancer chemotherapy and their clinical impact
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
New antimetabolites in cancer chemotherapy and their clinical impact
@en
New antimetabolites in cancer chemotherapy and their clinical impact.
@nl
type
label
New antimetabolites in cancer chemotherapy and their clinical impact
@en
New antimetabolites in cancer chemotherapy and their clinical impact.
@nl
prefLabel
New antimetabolites in cancer chemotherapy and their clinical impact
@en
New antimetabolites in cancer chemotherapy and their clinical impact.
@nl
P2860
P356
P1476
New antimetabolites in cancer chemotherapy and their clinical impact
@en
P2093
P2860
P2888
P356
10.1038/BJC.1998.747
P407
P478
78 Suppl 3
P577
1998-01-01T00:00:00Z